Eli Lilly Talks $2B+ Acquisition of Kelonia Therapeutics

Pharmaceutical giant Eli Lilly is reportedly in advanced discussions to acquire the biotech firm Kelonia Therapeutics for a sum exceeding $2 billion. The potential deal, if finalized, could be structured with performance-based payments tied to Kelonia's future milestones.

About Kelonia Therapeutics

Kelonia Therapeutics, based in Boston, is a clinical-stage biotechnology company. The firm focuses on developing a pipeline of genetic medicines designed to treat various diseases, with a specific emphasis on CAR-T cell therapies.

• CAR-T Therapies: These treatments function by modifying a patient's own immune cells, enabling them to recognize and destroy specific cancer cells.

Strategic Implications for Eli Lilly

Sources indicate that the acquisition would significantly bolster Eli Lilly's existing oncology portfolio. This move aims to strengthen the company's competitive standing within the rapidly expanding, yet highly competitive, cancer treatment market.

Eli Lilly's current cancer treatments and promising candidates include:

• Jaypirca
• Verzenio (a breast cancer drug)
• Other pipeline candidates

Deal Status and Reporting

• The Wall Street Journal reported the advanced talks on Sunday.
• The potential agreement could be reached as early as Monday.
• The deal structure may incorporate additional payments contingent upon Kelonia achieving specific developmental milestones.

Note: Reuters was unable to immediately verify the report, and neither Eli Lilly nor Kelonia Therapeutics responded to comment outside of regular business hours.